Zhejiang Haisen Pharmaceutical Co., Ltd.

SZSE:001367 Stock Report

Market Cap: CN¥2.8b

Zhejiang Haisen Pharmaceutical Past Earnings Performance

Past criteria checks 5/6

Zhejiang Haisen Pharmaceutical has been growing earnings at an average annual rate of 10.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.7% per year. Zhejiang Haisen Pharmaceutical's return on equity is 9.2%, and it has net margins of 27.6%.

Key information

10.4%

Earnings growth rate

3.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate7.7%
Return on equity9.2%
Net Margin27.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Zhejiang Haisen Pharmaceutical's (SZSE:001367) Shareholders May Want To Dig Deeper Than Statutory Profit

May 01
Zhejiang Haisen Pharmaceutical's (SZSE:001367) Shareholders May Want To Dig Deeper Than Statutory Profit

Recent updates

Zhejiang Haisen Pharmaceutical's (SZSE:001367) Shareholders May Want To Dig Deeper Than Statutory Profit

May 01
Zhejiang Haisen Pharmaceutical's (SZSE:001367) Shareholders May Want To Dig Deeper Than Statutory Profit

Revenue & Expenses Breakdown

How Zhejiang Haisen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:001367 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244341203424
30 Jun 244151173323
31 Mar 244061133620
31 Dec 233971053619
30 Sep 23390973519
30 Jun 23405973418
31 Mar 234241043116
01 Jan 234231083316
30 Sep 224171083412
30 Jun 224141073611
31 Mar 224011013411
31 Dec 21389943312
31 Dec 20285632711
31 Dec 1926669439
31 Dec 1824759429

Quality Earnings: 001367 has high quality earnings.

Growing Profit Margin: 001367's current net profit margins (27.6%) are higher than last year (24.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 001367's earnings have grown by 10.4% per year over the past 5 years.

Accelerating Growth: 001367's earnings growth over the past year (23.7%) exceeds its 5-year average (10.4% per year).

Earnings vs Industry: 001367 earnings growth over the past year (23.7%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 001367's Return on Equity (9.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies